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E-mail address: eohta@kitasato-u.ac.jp (E. Ohta).LRRK2 is the causal molecule for autosomal-dominant familial Parkinson’s disease, although its true
function, including its physiological substrates, remains unknown. Here, using in vitro kinase assay
with recombinant proteins, we demonstrated for the ﬁrst time that LRRK2 directly phosphorylates
Akt1, a central molecule involved in signal transduction for cell survival and prevention of apopto-
sis. Ser473, one of two amino acids essential for Akt1 activation, was the target site for LRRK2. A
knockdown experiment using intact cells also demonstrated LRRK2-mediated phosphorylation of
Akt1 (Ser473), suggesting that Akt1 is a convincing candidate for the physiological substrate of
LRRK2. The disease-associated mutations, R1441C, G2019S, and I2020T, exhibited reduced interac-
tion with, and phosphorylation of, Akt1, suggesting one possible mechanism for the neurodegener-
ation caused by LRRK2 mutations.
Structured summary of protein interactions:
LRRK2 phosphorylates Akt1 by protein kinase assay (View Interaction 1, 2, 3).
LRRK2 phosphorylates MBP by protein kinase assay (View Interaction 1, 2).
LRRK2 binds to Akt1 by pull down (View Interaction 1, 2, 3).
 2011 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Parkinson’s disease (PD) is the second most common neurode-
generative disorder caused by loss of nigrostriatal dopaminergic
neurons. Leucine-rich repeat kinase (LRRK2) is the gene responsi-
ble for autosomal-dominant PD, PARK8, which we originally
deﬁned by linkage analysis of a Japanese family (Sagamihara
family) [1–4]. LRRK2 is a 280-kDa multidomain-kinase molecule
consisting of LRR (leucine-rich repeat), ROC (Ras of complex),
COR (C-terminal ROC), kinase, and WD40 domains [5]. Most of
the disease-associated mutations have been reported in the ROC
and kinase domains. Patients with LRRK2mutations exhibit clinical
features indistinguishable from those of patients with sporadic PD,
and LRRK2 is postulated to be a key molecule in the etiology of the
disease. However, neither the true function of LRRK2 nor the mech-
anism of neurodegeneration resulting from its mutations has been
elucidated.
Accumulated data suggest that the kinase activity of LRRK2 may
play a key role in neurodegeneration [6,7]. Several candidatechemical Societies. Published by Emolecules have been reported to act as substrates for LRRK2.
LRRK2 itself can also serve as a substrate, and autophosphorylation
elevates its own kinase activity [8–14]. Other molecules reportedly
known to be LRRK2 substrates include the actin-cytoskeleton-re-
lated ERM (ezrin/radxin/moesin) proteins, b-tubulin, eukaryotic
initiation factor 4E-binding protein 1 (4E-BP1), and mitogen-acti-
vated kinase kinase 3, 4, 6, and 7 [15–20]. However, there is no
consensus regarding which of these molecules is the true physio-
logical substrate of LRRK2. For example, it has been reported that
LRRK2 may not be the major kinase responsible for phosphoryla-
tion of 4E-BP1 in mammalian cells [21].
Akt1 (also known as protein kinase B1) is a serine/threonine
kinase implicated in a variety of cellular events. In particular,
Akt1 is the central molecule that transduces signals from
receptors for growth factors and hormones to insure cell survival
and protection of cells from apoptosis [22,23]. In the present study,
we found that LRRK2 directly phosphorylated Akt1 at Ser473, an
essential site for Akt1 activation. Our results indicate that Akt1 is
one of the physiological substrates of LRRK2, and provide new
functional insight into LRRK2 and its role in neurodegeneration.lsevier B.V. All rights reserved.
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Fig. 1. LRRK2 directly interacts with and phosphorylates Akt1. (A) One hundred nanograms of recombinant human His-Akt1 (native or heat-denatured) was incubated with
50 ng of recombinant wild type GST-LRRK2 (molar ratio: 6.2:1) in the presence of radiolabeled ATP. The 32P-labeled proteins in the reaction mixture were detected by
autoradiography following SDS–PAGE. (B) GST-LRRK2 or GST alone was mixed with the recombinant His-Akt1 and subjected to pull-down assay by incubation with
glutathione agarose beads. The beads-bound proteins were subjected to Western analysis using antibodies against non-phosphorylated Akt1 and GST.
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2.1. In vitro phosphorylation of Akt1 by LRRK2
One hundred nanograms of recombinant human Akt1 (His-
tagged protein) (Calbiochem) was incubated with 50 ng of recom-
binant human LRRK2 [glutathione-S transferase (GST)-tagged
protein consisting of amino acid residues 970–2527; either wild-
type, R1441C mutant, G2019 mutant, or I2020T mutant] (Invitro-
gen) in 25 ll of reaction mixture [40 mM Tris–HCl (pH 7.6),
2 mM dithiothreitol, 10 mM MgCl2, and 5 lM ATP including 3 lCi
of [c-32P]ATP (GE Healthcare)]. After incubation at 30 C for
30 min, the reaction was stopped by boiling in the sample-loading
buffer for sodium dodecyl sulfate-polyacrylamide gel electropho-
resis (SDS–PAGE). The 32P-labeled proteins were detected by auto-
radiography followed by SDS–PAGE, as described previously [24].
In some experiment, bovine myelin basic protein (MBP) (Sigma)
was used as the substrate of LRRK2. For Western analysis,
in vitro phosphorylation was performed without radiolabeled c-
ATP.
2.2. In vitro GST pull-down assay
Recombinant GST-LRRK2 or GST alone was mixed with the
recombinant His-Akt1 and incubated with glutathione agarose
beads overnight at 4 C in 100 ll of TNE buffer [50 mM Tris–HClA B
Fig. 2. LRRK2 phosphorylates Akt1 at Ser473. (A) Recombinant human His-Akt1 (native
cold c-ATP. The phospho-Akt1 (Thr308), phospho-Akt1 (Ser473), and total Akt1 were
representation of the phosphorylation level of Akt1 [phospho-Akt1 (Thr308)/total Akt1(pH7.4), 150 mM NaCl, 1% (v/v) Nonidet P-40, 1 mM EDTA]. After
centrifugation, the supernatant was removed, and the beads were
washed three times with TNE buffer. The bound proteins were
eluted from the beads by boiling in 50 ll of SDS–PAGE sample buf-
fer. The eluted samples were subjected to Western analysis using
antibodies against non-phosphorylated Akt1 (Cell Signaling) and
GST (Advanced Targeting Systems).
2.3. Western analysis
Proteins after in vitro phosphorylation and those in cell lysates
were subjected to SDS–PAGE using a 5–20% gradient of e-PAGEL
(ATTO), blotted onto polyvinylidene ﬂuoride membrane, and ana-
lyzed using antibodies with the following speciﬁcities: LRRK2
(MJFF2, c41-2) (Epitomics), phospho-Akt1 (Thr308) (Cell Signal-
ing), phospho-Akt1 (Ser473) (Cell Signaling), non-phosphorylated
Akt1, phospho-4E-BP1 (Thr37/46) (Cell Signaling), non-phosphory-
lated 4E-BP1 (Cell Signaling), and horseradish peroxidase (HRP)-la-
beled secondary antibody against rabbit IgG (BioLegend).
HRP-labeled antibody against beta-actin (Abcam) was used as an
internal control.
2.4. Knockdown of LRRK2
For knockdown of endogenous LRRK2 expressed by neuroblas-
toma SH-SY5Y, cells were transfected with 25 mer of Stealth RNAior heat-denatured) was incubated with recombinant GST-LRRK2 in the presence of
detected by Western analysis using speciﬁc antibodies against each. (B) Graphical
and phospho-Akt1 (Ser473)/total Akt1] (n = 2).
A B
Fig. 3. Knockdown of endogenous LRRK2 expression diminishes Akt1 phosphorylation in intact cells. (A) SH-SY5Y cells were transfected with either the LRRK2-speciﬁc RNAi
or the RNAi control. After 48 h of transfection, cell lysates were prepared and subjected toWestern analysis using antibodies against LRRK2, phospho-Akt1 (Ser473), phospho-
Akt1 (Thr308), non-phosphorylated Akt1, phospho-4E-BP1 (Thr37/46), non-phosphorylated 4E-BP1, and beta-actin as a control. (B) Graphical representation of the LRRK2-
protein level, Akt1-phosphorylation level, and 4E-BP1-phosphorylation level. Stars represent statistical comparisons by one-way ANOVA (n = 3); ⁄: p < 0.05, ⁄⁄: p < 0.005.
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or with an RNAi-control with the scrambled sequence using
FuGENEHD Transfection Reagent (Roche). After 48 h of transfec-
tion, the cells were suspended in cell lysis buffer [20 mM
Tris–HCl (pH 8.2) containing 1% Triton X-100, 0.25 mM sucrose,
10 mM EGTA, 2 mM EDTA, 1 tablet of Complete mini protease
inhibitor cocktail (Roche), and 1 tablet of PhosSTOP (Roche)].
Cell lysates were obtained by centrifugation at 10 000g for
10 min at 4 C and subjected to Western analysis using anti-LRRK2
antibody. A SH-SH5Y clone stably and uniformly overexpressing
the V5-tagged wild-type full-length LRRK2 was describedA B
Fig. 4. Knockdown of overexpressed LRRK2 reduces Akt1 phosphorylation. (A) A SH-SY
LRRK2-speciﬁc RNAi or the RNAi control. After 48 h of transfection, cell lysates were pre
Akt1 (Ser473), phospho-Akt1 (Thr308), non-phosphorylated Akt1, and beta-actin as a c
control. (B) Graphical representation of the LRRK2-protein level and Akt1-phosphoryla
p < 0.005.previously [25,26]. A SH-SY5Y clone expressing only the neomycin
gene was used as a vector control. LRRK2 was knocked down using
the same procedure as that described above.
3. Results
3.1. LRRK2 directly interacts with and phosphorylates Akt1
We have previously reported that LRRK2 exerts a protective ef-
fect against H2O2-induced apoptosis [26]. Akt1 is a signal-transduc-
ing molecule playing a central role in cell survival and inhibition of5Y clone stably overexpressing wild-type LRRK2 was transfected with either the
pared and subjected to Western analysis using antibodies against LRRK2, phospho-
ontrol. A SH-SY5Y clone expressing only the neomycin gene was used as a vector
tion level. Stars represent statistical comparisons by one-way ANOVA (n = 3); ⁄⁄:
A B C
D E
Fig. 5. Mutant LRRK2 exhibits lower Akt1-phosphorylation activity than wild-type LRRK2. (A) Recombinant His-Akt1 (native) was incubated with recombinant GST-LRRK2 of
the wild-type (WT), G2019S mutant, I2020T mutant, or R1441C mutant in the presence of cold c-ATP. The phosphorylated Akt1 was subjected to Western analysis using
antibodies speciﬁc to phospho-Akt1 (S473). (B) Graphical representation of the Akt1 (S473) phosphorylation level. Stars represent statistical comparisons by one-way ANOVA
(n = 3); ⁄⁄: p < 0.005. (C) Bovine MBP was incubated with recombinant LRRK2 in the presence of radiolabeled ATP. 32P-Labeled proteins in the reaction mixture were detected
by autoradiography following SDS–PAGE. Relative LRRK2 kinase activities to that of WT LRRK2 are shown. Stars represent statistical comparisons by one-way ANOVA (n = 3);
⁄⁄: p < 0.005. (D) Recombinant GST-tagged wild-type (WT), G2019S, I2020T, or R1441C LRRK2 was mixed with the recombinant His-Akt1 and subjected to GST pull-down
assay by incubation with glutathione agarose beads. The proteins bound to the beads were subjected to Western analysis using antibodies against non-phosphorylated Akt1
and GST. (E) Graphical representation of the bound Akt1 normalized to GST-LRRK2.
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various kinases such as 30-phosphoinositide-dependent kinase-1
(PDK-1), mammalian target of rapamycin complex 2 (mTORC2),
and integrin-linked kinase (ILK) [23,27]. To examine the possibility
that the LRRK2-mediated protectivity against apoptosis involves
Akt1 activation, recombinant human Akt1 (His-tagged protein)
was subjected to in vitro [c-32P]ATP phosphorylation assay with re-
combinant human LRRK2 (GST-tagged wild-type protein consisting
of all the functional domains in the stretch incorporating amino
acid residues 970–2527). As reported previously, both Akt1 and
LRRK2 exhibited a signiﬁcant level of autophosphorylation
(Fig. 1A, lanes 1 and 3). We found that LRRK2 directly and effec-
tively phosphorylated the heat-denatured (i.e., autophosphoryla-
tion-disrupted) Akt1 molecule (Fig. 1A, lane 6). On the other
hand, Akt1 did not phosphorylate heat-denatured LRRK2 (Fig. 1A,
lane 4), indicating that Akt1 is the downstream substrate of LRRK2.
Curiously, heat-inactivated LRRK2 appeared to promote Akt1 phos-
phorylation, although the extent of which was signiﬁcantly lower
than that mediated by active LRRK2. The GST-pull down assay con-
ﬁrmed the direct interaction between LRRK2 and Akt1 (Fig. 1B).
3.2. LRRK2 phosphorylates Akt1 at Ser473
The phosphorylation of Thr308 by PDK-1 and phosphorylation
of Ser473 by mTORC2 and ILK are well known to be involved inthe activation of Akt1 [23,27]. To clarify whether LRRK2 phosphor-
ylates these sites, the recombinant Akt1 that had been phosphory-
lated by recombinant LRRK2 was subjected to Western analysis
using antibodies speciﬁc to each Akt1-phosphoamino acid. As
shown in Fig. 2, LRRK2 scarcely phosphorylated the heat-dena-
tured (i.e., autophosphorylation-disrupted) Akt1 at Thr308, i.e., at
a degree of phosphorylation much weaker than that of autophos-
phorylation. On the other hand, LRRK2 effectively phosphorylated
the heat-denatured Akt1 at Ser473 [about 7.3-fold of autophospho-
rylation in the phosphorylation level (phospho-Akt1/total Akt1)].
3.3. Knockdown of LRRK2 diminishes Akt1 phosphorylation in intact
cells
To conﬁrm the kinase activity of LRRK2 on Akt1 in intact cells,
we next performed a LRRK2-knockdown experiment using neuro-
blastoma SH-SY5Y cells. As shown in Fig. 3, transfection of LRRK2-
speciﬁc RNAi into the cells reduced the level of LRRK2 protein to
46% in comparison with the use of an RNAi control. The knockdown
of LRRK2 resulted in a marked reduction of phospho-Akt1 (Ser473),
whereas it had no inﬂuence on the total level of Akt1 protein. Con-
sequently, the phosphorylation level of Akt1 [phospho-Akt1
(Ser473)/total Akt1] in the cells with LRRK2-knockdown was
reduced to 51% in comparison with that in the RNAi control cells.
The LRRK2-knockdown also diminished the phosphorylation of
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than that observed for Akt1 (71% in comparison with the control
RNAi).
We also analyzed a SH-SY5Y clone stably and uniformly over-
expressing the full-length LRRK2 [25,26]. This clone exhibited
3.4-fold higher Akt1 (Ser473) phosphorylation than the vector-
control clone (Fig. 4). The knockdown of the overexpressed LRRK2
in this clone (46% in comparison with the control RNAi) resulted in
a marked reduction of the phosphorylation level of Akt1 [phospho-
Akt1 (Ser473)/total Akt1] (55% in comparison with the control
RNAi). Altogether, these results indicated that LRRK2 indeed phos-
phorylated Akt1 at Ser473 in intact cells.
3.4. Mutant LRRK2 exhibits reduced Akt1-phosphorylation activity
than wild-type LRRK2
Finally, we examined the inﬂuence of disease-associated LRRK2
mutations on its kinase activity toward Akt1. The recombinant
Akt1 was phosphorylated by the recombinant LRRK2 with the
three known mutations, i.e., R1441C in the ROC domain, G2019S
in the kinase domain, and I2020T in the kinase domain. We found
that the three LRRK2 mutants exhibited signiﬁcantly weaker ki-
nase activity of Akt1 (Ser473)-phosphorylation than the wild-type
LRRK2 (Fig. 5A and B). When MBP was used as substrate, on the
other hand, G2019S as well as I2020T mutant LRRK2 exhibited
much stronger kinase activity than the wild-type LRRK2, in accor-
dance with several other reports [6] (Fig. 5C). The pull-down assay
using the three LRRK2 mutants showed that the reduced kinase
activity toward Akt1 (Ser473) was ascribable to impaired ability
to bind Akt1, particularly in the case of G2019S LRRK2 (Fig. 5D
and E).4. Discussion
LRRK2 is postulated to be a key molecule in the etiology of both
familial and sporadic PD. However, the molecular mechanism
whereby mutant LRRK2 causes loss of dopaminergic neurons has
not yet been conﬁrmed. This is due to the lack of consensus about
the true physiological substrate or true function of LRRK2. Here, for
the ﬁrst time, we demonstrated that LRRK2 interacts with and
phosphorylates Akt1, a central molecule that transduces signals
necessary for cell survival. In vitro pull-down and kinase assays
using recombinant proteins proved that Akt1 is the direct down-
stream substrate of LRRK2. LRRK2-mediated phosphorylation of
Akt1 was also demonstrated in intact cells, suggesting that Akt1
is a convincing candidate for the physiological substrate of LRRK2.
Like mTORC2 and ILK [23,27], LRRK2 phosphorylated Akt1 at
Ser473, one of the two amino acids essential for Akt1activation.
Therefore, it is possible that LRRK2 may activate Akt1 in concert
with PDK-1, which phosphorylates another essential amino acid,
Thr308, in a manner that is dependent on phosphatidylinositol-
3,4,5-triphosphate [23]. The serine is rather unique as a target site
for LRRK2, which has previously been thought to preferentially
phosphorylate Thr rather than Ser, based on the phosphorylation
sites of known substrates [12,15,28]. The amino acid sequence sur-
rounding Ser473 is also distinct from those reported as the LRRK2
consensus phosphorylation motif [12,28].
Once activated, Akt1 phosphorylates and negatively regulates a
wide variety of apoptosis-associated molecules such as Bad, Bax,
Bim, caspase-9, and forkhead box factor FoxO1. In addition, Akt1
activates several signal-transduction cascades for cell survival,
which are mediated by ASK-1, GSK-3b, or NFrB [23,27,29–32].
Notably, LRRK2 reportedly activates NFrB, although any involve-
ment of Akt1 has not been investigated [18,20,33,34]. We have re-
ported previously that LRRK2 has an ability to protect cells againstH2O2-induced apoptosis, and that knockdown of LRRK2 abrogates
this ability [26]. It is possible that the cell-protective ability of
LRRK2 is exerted through phosphorylation and activation of Akt1,
which in turn activates one or several of the downstream signal
cascades described above. On the other hand, there has been some
controversy as to whether LRRK2 is protective or toxic for cells
[14,26,33,35–37]. LRRK2 has been reported to activate FoxO1
[38] in Drosophila, but in this case resulting in elevated expression
of Bim and neural cell death. The LRRK2-mediated phosphorylation
of Akt1 might transduce different downstream signals depending
on the source of the cells, growth conditions, and presence of oxi-
dative stress or other factors.
It is noteworthy that all the disease-associated mutations ana-
lyzed here, i.e., R1441C, G2019S, and I2020T, reduced both interac-
tion with, and phosphorylation of, Akt1. In particular, G2019S
LRRK2, which exerts hyperkinase activity toward most known sub-
strates, showed diminished kinase activity toward Akt1 (Ser473),
being ascribable to impaired Akt1-binding ability. Our results
suggest that neurons expressing the mutant LRRK2 may exhibit
lower resistance to apoptosis, due to lower phosphorylation and
activation of Akt1, than those expressing the wild-type LRRK2.
Furthermore, a transfection experiment using a combination of
wild-type and mutant LRRK2 revealed that a mutation at one of
the two LRRK2 alleles was enough to explain the signiﬁcant reduc-
tion in both Akt1 phosphorylation and resistance to apoptosis
(unpublished data), suggesting one possible mechanism for neuro-
degeneration in the dominant-heredity form of PD, PARK8.
Acknowledgments
This study was supported by the Japanese Ministry of Education
and Technology (Grant-in-Aid for Young Scientists, B-21790848),
by Kanagawa Nanbyou Study Foundation (Grant-in-Aid 2009),
and by Kitasato University (Research Grant for Young Researchers
of 2010). The authors thank Ms. Y. Iwashita and M. Nakanishi for
technical assistance.
References
[1] Funayama, M., Hasegawa, K., Kowa, H., Saito, M., Tsuji, S. and Obata, F. (2002) A
new locus for Parkinson’s disease (PARK8) maps to chromosome 12p11.2–
q13.1. Ann. Neurol. 51, 296–301.
[2] Zimprich, A., Biskup, S., Leitner, P., Lichtner, P., Farrer, M., Lincoln, S.,
Kachergus, J., Hulihan, M., Uitti, R.J., Calne, D.B., Stoessl, A.J., Pfeiffer, R.F.,
Patenge, N., Carbajal, I.C., Vieregge, P., Asmus, F., Müller-Myhsok, B., Dickson,
D.W., Meitinger, T., Strom, T.M., Wszolek, Z.K. and Gasser, T. (2004) Mutations
in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic
pathology. Neuron 44, 601–607.
[3] Paisan-Ruiz, C., Jain, S., Evans, E.W., Gilks, W.P., Simon, J., van der Brug, M.,
Lopez de Munain, A., Aparicio, S., Gil, A.M., Khan, N., Johnson, J., Martinez, J.R.,
Nicholl, D., Carrera, I.M., Pena, A.S., de Silva, R., Lees, A., Martí-Massó, J.F.,
Pérez-Tur, J., Wood, N.W. and Singleton, A.B. (2004) Cloning of the gene
containing mutations that cause PARK8-linked Parkinson’s disease. Neuron 44,
595–600.
[4] Funayama, M., Hasegawa, K., Ohta, E., Kawashima, N., Komiyama, M., Kowa, H.,
Tsuji, S. and Obata, F. (2005) An LRRK2 mutation as a cause for the
parkinsonism in the original PARK8 family. Ann. Neurol. 57, 918–921.
[5] Meylan, E. and Tschopp, J. (2005) The RIP kinases: crucial integrators of
cellular stress. Trends Biochem. Sci. 30, 151–159.
[6] Greggio, E. and Cookson, M.R. (2009) Leucine-rich repeat kinase 2 mutations
and Parkinson’s disease: three questions. ASN Neuro 1, e00002.
[7] Seol, W. (2010) Biochemical and molecular features of LRRK2 and its
pathophysiological roles in Parkinson’s disease. BMB Rep. 43, 233–244.
[8] West, A.B., Moore, D.J., Biskup, S., Bugayenko, A., Smith, W.W., Ross, C.A.,
Dawson, V.L. and Dawson, T.M. (2005) Parkinson’s disease-associated
mutations in leucine-rich repeat kinase 2 augment kinase activity. Proc.
Natl. Acad. Sci. USA 102, 16842–16847.
[9] Gloeckner, C.J., Kinkl, N., Schumacher, A., Braun, R.J., O’Neill, E., Meitinger, T.,
Kolch, W., Prokisch, H. and Uefﬁng, M. (2006) The Parkinson disease causing
LRRK2 mutation I2020T is associated with increased kinase activity. Hum. Mol.
Genet. 15, 223–232.
[10] Greggio, E., Jain, S., Kingsbury, A., Bandopadhyay, R., Lewis, P., Kaganovich, A.,
van der Brug, M.P., Beilina, A., Blackinton, J., Thomas, K.J., Ahmad, R., Miller,
D.W., Kesavapany, S., Singleton, A., Lees, A., Harvey, R.J., Harvey, K. and
2170 E. Ohta et al. / FEBS Letters 585 (2011) 2165–2170Cookson, Y. (2010) Kinase activity is required for the toxic effects of mutant
LRRK2/dardarin. Neurobiol. Dis. 23, 329–341.
[11] Ito, G., Okai, T., Fujino, G., Takeda, K., Ichijo, H., Katada, T. and Iwatsubo, T. (2007)
GTP binding is essential to the protein kinase activity of LRRK2, a causative gene
product for familial Parkinson’s disease. Biochemistry 46, 1380–1388.
[12] Kamikawaji, S., Ito, G. and Iwatsubo, T. (2009) Identiﬁcation of the
autophosphorylation sites of LRRK2. Biochemistry 48, 10963–10975.
[13] Li, X., Moore, D.J., Xiong, Y., Dawson, T.M. and Dawson, V.L. (2010)
Reevaluation of phosphorylation sites in the Parkinson disease-associated
leucine-rich repeat kinase 2. J. Biol. Chem. 285, 29569–29576.
[14] West, A.B., Moore, D.J., Choi, C., Andrabi, S.A., Li, X., Dikeman, D., Biskup, S.,
Zhang, Z., Lim, K.L., Dawson, V.L. and Dawson, T.M. (2007) Parkinson’s disease-
associated mutations in LRRK2 link enhanced GTP-binding and kinase
activities to neuronal toxicity. Hum. Mol. Genet. 16, 223–232.
[15] Jaleel, M., Nichols, R.J., Deak, M., Campbell, D.G., Gillardon, F., Knebel, A. and
Alessi, D.R. (2007) LRRK2 phosphorylates moesin at threonine-558:
characterization of how Parkinson’s disease mutants affect kinase activity.
Biochem. J. 405, 307–317.
[16] Imai, Y., Gehrke, S., Wang, H.Q., Takahashi, R., Hasegawa, K., Oota, E. and Lu, B.
(2008) Phosphorylation of 4E-BP by LRRK2 affects the maintenance of
dopaminergic neurons in Drosophila. EMBO J. 27, 2432–2443.
[17] Gandhi, P.N., Wang, X., Zhu, X., Chen, S.G. and Wilson-Delfosse, A.L. (2008) The
Roc domain of leucine-rich repeat kinase 2 is sufﬁcient for interaction with
microtubules. J. Neurosci. Res. 86, 1711–1720.
[18] Gloeckner, C.J., Schumacher, A., Boldt, K. and Uefﬁng, M. (2009) The Parkinson
disease-associated protein kinase LRRK2 exhibits MAPKKK activity and
phosphorylates MKK3/6 and MKK4/7, in vitro. J. Neurochem. 109, 959–968.
[19] Gillardon, F. (2009) Leucine-rich repeat kinase 2 phosphorylates brain tubulin-
beta isoforms and modulates microtubule stability-a point of convergence in
parkinsonian neurodegeneration? J. Neurochem. 110, 1514–1522.
[20] Hsu, C.H., Chan, D., Greggio, E., Saha, S., Guillily, M.D., Ferree, A., Raghavan, K.,
Shen, G.C., Segal, L., Ryu, H., Cookson, M.R. and Wolozin, B. (2010) MKK6 binds
and regulates expression of Parkinson’s disease-related protein LRRK2. J.
Neurochem. 112, 1593–1604.
[21] Kumar, A., Greggio, E., Beilina, A., Kaganovich, A., Chan, D., Taymans, J.M.,
Wolozin, B. and Cookson, M.R. (2010) The Parkinson’s disease associated
LRRK2 exhibits weaker in vitro phosphorylation of 4E-BP compared to
autophosphorylation. PLoS ONE 5, e8730.
[22] Dudek, H., Datta, S.R., Franke, T.F., Birnbaum, M.J., Yao, R., Cooper, G.M., Segal,
R.A., Kaplan, D.R. and Greenberg, M.E. (1997) Regulation of neuronal survival
by the serine-threonine protein kinase Akt. Science 275, 661–665.
[23] Manning, B.D. and Cantley, L.C. (2007) AKT/PKB signaling: navigating
downstream. Cell 129, 1261–1274.
[24] Kawakami, F., Yamaguchi, A., Suzuki, K., Yamamoto, T. and Ohtsuki, K. (2008)
Biochemical characterization of phospholipids, sulfatide and heparin as potent
stimulators for autophosphorylation of GSK-3beta and the GSK-3beta-
mediated phosphorylation of myelin basic protein in vitro. J. Biochem. 143,
359–367.[25] Ohta, E., Katayama, Y., Kawakami, F., Yamamoto, M., Tajima, K., Maekawa, T.,
Iida, N., Hattori, S. and Obata, F. (2009) I2020T leucine-rich repeat kinase 2, the
causative mutant molecule of familial Parkinson’s disease, has a higher
intracellular degradation rate than the wild-type molecule. Biochem. Biophys.
Res. Commun. 390, 710–715.
[26] Ohta, E., Kubo, M. and Obata, F. (2010) Prevention of intracellular degradation
of I2020T mutant LRRK2 restores its productivity against apoptosis. Biochem.
Biophys. Res. Commun. 391, 242–247.
[27] Troussard, A.A., Mawji, N.M., Ong, C., Mui, A., Arnaud St., R. and Dedhar, S.
(2003) Conditional knock-out of integrin-linked kinase demonstrates an
essential role in protein kinase B/Akt activation. J. Biol. Chem. 278, 22374–
22378.
[28] Pungaliya, P.P., Bai, Y., Lipinski, K., Anand, V.S., Sen, S., Brown, E.L., Bates, B.,
Reinhart, P.H., West, A.B., Hirst, W.D. and Braithwaite, S.P. (2010)
Identiﬁcation and characterization of a leucine-rich repeat kinase 2 (LRRK2)
consensus phosphorylation motif. PLoS ONE 5, e13672.
[29] Kim, A.H., Khursigara, G., Sun, X., Franke, T.F. and Chao, M.V. (2001) Akt
phosphorylates and negatively regulates apoptosis signal-regulating kinase 1.
Mol. Cell. Biol. 21, 893–901.
[30] Ozes, O.N., Mayo, L.D., Gustin, J.A., Pfeffer, S.R., Pfeffer, L.M. and Donner, D.B.
(1999) NF-jB activation by tumour necrosis factor requires the Akt serine-
threonine kinase. Nature 401, 82–85.
[31] Romashkova, J.A. and Makarov, S.S. (1999) NF-kappaB is a target of AKT in
anti-apoptotic PDGF signalling. Nature 401, 86–90.
[32] Cross, D.A., Alessi, D.R., Cohen, P., Andjelkovich, M. and Hemmings, B.A. (1995)
Inhibition of glycogen synthase kinase-3 by insulin mediated by protein
kinase B. Nature 378, 785–789.
[33] Liou, A.K., Leak, R.K., Li, L. and Zigmond, M.J. (2008) Wild-type LRRK2 but not
its mutant attenuates stress-induced cell death via ERK pathway. Neurobiol.
Dis. 32, 116–124.
[34] Gardet, A., Benita, Y., Li, C., Sands, B.E., Ballester, I., Stevens, C., Korzenik, J.R.,
Rioux, J.D., Daly, M.J., Xavier, R.J. and Podolsky, D.K. (2010) LRRK2 is involved
in the IFN-gamma response and host response to pathogens. J. Immunol. 185,
5577–5585.
[35] Smith, W.W., Pei, Z., Jiang, H., Dawson, V.L., Dawson, T.M. and Ross, C.A. (2006)
Kinase activity of mutant LRRK2 mediates neuronal toxicity. Nat. Neurosci. 9,
1231–1233.
[36] Smith, W.W., Pei, Z., Jiang, H., Moore, D.J., Liang, Y., West, A.B., Dawson, V.L.,
Dawson, T.M. and Ross, C.A. (2005) Leucine-rich repeat kinase 2 (LRRK2)
interacts with parkin and mutant LRRK2 induces neuronal degeneration. Proc.
Natl. Acad. Sci. USA 102, 18676–18681.
[37] Iaccarino, C., Crosio, C., Vitale, C., Sanna, G., Carri, M.T. and Barone, P. (2007)
Apoptotic mechanisms in mutant LRRK2-mediated cell death. Hum. Mol.
Genet. 16, 1319–1326.
[38] Kanao, T., Venderova, K., Park, D.S., Unterman, T., Lu, B. and Imai, Y. (2010)
Activation of FoxO by LRRK2 induces expression of proapoptotic proteins and
alters survival of postmitotic dopaminergic neuron in Drosophila. Hum. Mol.
Genet. 19, 3747–3758.
